|
The company's shares rose about 34 percent to $35.01 in premarket
trading on Wednesday.
Patients treated with 60 mg of the drug, ITI-007, showed improvement
over placebo. The 40 mg dosage, however, failed to achieve
statistical significance, the company said in a statement.
Schizophrenia is characterized by reduced brain function, with
patients experiencing a range of psychological symptoms such as
hallucinations, delusions and changes in behavioral patterns.
The disorder affects over 20 million people worldwide, according to
the World Health Organization.
Intra-Cellular also reported results from another trial, which
showed the drug could have reduced risks of side effects such as
movement and metabolic disorders or cardiovascular effects often
observed with other antipsychotics.
The company is also evaluating ITI-007 in another late-stage study
to treat depression associated with bipolar disorder.
[to top of second column] |
Intra-Cellular Therapies shares closed at $26.11 on the Nasdaq on
Tuesday.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Anil D'Silva)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
